anus cancer
MONDO:0001879
A malignant neoplasm involving the anus
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
MONDO disease family
Recruiting studies by city
Trial status
Trial phase
Study start year
Investigated drug interventions
Anal cancer
Anal cancer is a cancer which arises from the anus, the distal opening of the gastrointestinal tract. Symptoms may include bleeding from the anus or a lump near the anus. Other symptoms may include pain, itchiness, or discharge from the anus. A change in bowel movements may also occur. Risk factors include human papillomavirus (HPV), HIV/AIDS, receptive anal sex, smoking, and many sexual partners. Anal cancer is typically a squamous cell carcinoma. Other types include adenocarcinoma, small cell carcinoma, and melanoma. Diagnosis is suspected based on physical examination and confirmed by tissue biopsy. Prevention includes avoiding risk factors and HPV vaccination. Standard treatment may include radiation therapy, chemotherapy, and surgery. About 10,930 people are diagnosed a year in the United States, representing about 0.5% of new cancers. Onset is typically after the age of 45. Women are affected more often than men. The number of cases has increased since the 1990s. The five-year survival rate in the United States is 71%.
Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.Drugs being studied
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.